How We Treat Autoimmune Small Fiber Polyneuropathy with Immunoglobulin Therapy
Intravenous immunoglobulin therapy is FDA approved for the immune-mediated peripheral nerve disorders Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. Immunoglobulin therapy has been used increasingly with significant efficacy in the treatment of patients with disabling autoimmune forms of dysautonomia, which are most often small fiber (autonomic and/or sensory) polyneuropathies. It is recognized by most who treat these disorders, however, that patients with autonomic dysfunction treated with intravenous immunoglobulin therapy develop aseptic meningitis or severe lingering headache more frequently than other patient populations when this therapy is dosed in the traditional fashion. We discuss our combined 27 years of experience with the use of immunoglobulin and other immune modulatory therapy in patients with autoimmune small fiber polyneuropathy.Eur Neurol 2018;80:304 –310
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI major bleeding. VOYAGER PAD is the only study to show a significant benefit...
This study confirmed that both venlafaxine XR and trazodone OAD may represent a valid treatment option for patients with MDD.
This double-blind placebo-controlled, fixed/flexible-dose phase 2 trial assessed the efficacy, safety, and tolerability of cariprazine vs. placebo for depressive episodes associated with bipolar I or II disorder. Primary endpoint was change in Montgomery–Åsberg Depression Rating Scale (MADRS) total scores (baseline to week 8), and secondary endpoint was mean Clinical Global Impressions-Improvement score (week 8). Patients were randomized (N = 233) 1:1:1 to placebo, ‘low-dose’ 0.25–0.5 mg/day or ‘high-dose’ 1.5–3.0 mg/day cariprazine. Adverse events...
Publication date: Available online 26 March 2020Source: Journal of Clinical NeuroscienceAuthor(s): Srdjan Ljubisavljevic, Jasna Zidverc Trajkovic
AbstractMigraine headache is a common, chronic, debilitating disease with a complex etiology. Current therapy for migraine headache comprises either treatments targeting acute migraine pain or prophylactic therapy aimed at increasing the length of time between migraine episodes. Recent evidence suggests that calcium gene-related peptide (CGRP) is a critical component in the pathogenesis of migraines. Fremanezumab, a monoclonal antibody against CGRP, was recently approved by the Food and Drug Administration (FDA) after multiple studies showed that it was well-tolerated, safe, and effective in the treatment of migraines. Fur...
Conclusion Various skull base tumors involving MCF with extension to adjacent sites can be successfully resected using the TZ-MCF approach in a multidisciplinary fashion. This approach yields optimal exposure and permits excellent tumor control with acceptable CN and neurological morbidity. [...] Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals: Table of contents | Abstract | Full text
Although research has shown little difference between manual and sham acupuncture, use of a nonpenetrating sham intervention in acupuncture-na ï ve subjects could explain a new study's positive results.Medscape Medical News
Symptoms like shortness of breath, chest tightness and headaches can occur with stress and COVID-19. Here's how to differentiate them.
Conditions: Trauma Injury; Brain Injuries; Abdominal Sepsis; Pancreatitis; Meningitis; Encephalitis; Seizures; Acute Respiratory Distress Syndrome Interventions: Drug: Control; Drug: Antiseptic Solution; Drug: Bacteriophage Sponsor: Northern State Medical University Active, not recruiting
Condition: Chronic Migraine Intervention: Sponsors: IRCCS National Neurological Institute " C. Mondino " Foundation; Ministry of Health, Italy Completed